Wolverine Stack

The Wolverine Stack is a single vial combining two peptides: BPC-157 and TB-500, a synthetic seven-amino-acid fragment of thymosin beta-4. It is given as one subcutaneous injection a day rather than two separate shots. The argument for pairing them is that they act on different but overlapping repair pathways. BPC-157 has been studied for tendon, ligament, and gut tissue, and TB-500 acts as a G-actin-sequestering peptide associated with cell migration and tissue revascularization. Both bodies of evidence are animal-heavy, and there is no published peer-reviewed study on this exact two-peptide combination.

No. Neither BPC-157 nor TB-500 is FDA-approved, and neither has been evaluated by the FDA for diagnosing, treating, curing, or preventing any disease. They are sold for research use, and when used clinically they are prescribed off-label by a licensed provider who has evaluated you first. Not FDA-approved does not mean illegal, and it does not automatically mean unsafe. It means neither peptide has gone through the full drug-approval pathway, and there is no completed published human efficacy trial for either one. We treat this stack as investigational and say so before anyone starts.

A typical cycle runs 4 to 8 weeks. Four weeks is usual for something acute like a recent strain, and eight for a longer-standing problem such as a persistent tendinopathy or post-surgical recovery, with a break before deciding whether to repeat. Cycle length is matched to the issue rather than to a fixed calendar. If eight weeks produced no functional improvement, running a longer course is less useful than revisiting the diagnosis. You can read how cycle decisions get made across our protocols in our peptide cycling guide.

Once daily. Because both peptides are combined in a single vial, that is one subcutaneous injection a day rather than two. The dose itself is provider-determined and set per individual protocol after evaluation, so it is not a number you should carry over from someone else's regimen or from a forum. Consistency matters more than timing with this stack, since the reported effects build over weeks of steady use rather than showing up after a single dose.

Subcutaneously, and when it is reasonable to do so we dose near the area of concern. Local exposure appears to matter in the animal work and clinical practice has followed that, though human evidence comparing local against systemic placement is limited. Near means the subcutaneous tissue in that region, not into a joint or directly into a tendon. When there is no specific target area, or the area is not practical to inject, the standard subcutaneous sites apply. Rotate sites rather than using the same spot daily, because this is a daily protocol and repeated injection into one area changes how the tissue absorbs.

It is a nickname, not a clinical term. The combination picked up the name because of the comic-book character associated with rapid healing, and it stuck in fitness and recovery circles before it was ever used in a medical setting. The name oversells it, which is worth saying plainly. These peptides are studied for tissue repair support, the human evidence is thin, and nobody heals like a comic-book character. We use the term because it is what patients search for and ask about, not because it describes what the stack does.

No, and it is not used for that. This is a recovery and tissue-repair protocol, not an anabolic one. Neither BPC-157 nor TB-500 is a growth hormone, a growth hormone secretagogue, or a steroid, and neither one adds lean mass on its own. What patients report is faster apparent recovery from soft-tissue strains and reduced soreness and stiffness, which can let you train more consistently. Any muscle you build still comes from the training. One important caveat: both peptides appear on prohibited substance lists for tested athletes under USADA and WADA, so we do not recommend this protocol for anyone subject to drug testing.